Clinical Trials Directory

Trials / Completed

CompletedNCT03671291

Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV

National Survey on Missed Opportunities to Pre-exposure Prophylaxis for Prevention of Human Immunodeficiency Virus-infection.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
596 (actual)
Sponsor
French National Agency for Research on AIDS and Viral Hepatitis · Other Government
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Missed opportunity to pre-exposure prophylaxis is a survey study that will be addressed to newly infected with human immunodeficiency virus (HIV) persons. The purposes of this study is to understand why despite the fact that pre-exposure prophylaxis exist, these persons have been contaminated with HIV.

Detailed description

Pre-exposure prophylaxis is a new strategy to prevent the occurrence of new cases of HIV. This prophylaxis strategy is based on taking antiretroviral drugs (ARV) before and after exposition to a risk of HIV infection which can reduce drastically the contamination with HIV. A certain groups of population based on their sexual orientation, for instance man who have sex with man (MSM), is among the groups that are highly exposed to this risk. To reduce this risk, French national regulatory authority (ANSM), firstly through temporary usage recommendation followed by a marketing authorization extension, allowed the prescription of these antiretroviral molecules to persons presenting eligibility criteria as defined by regulatory authority. Despite these preventive measures, the incidence of HIV such as the MSM group still high. The missed opportunity studies has as objectives to try to disentangle real obstacles of PrEP use in France and to optimize PrEP criteria if needed.

Conditions

Interventions

TypeNameDescription
BEHAVIORALself-administrated questionnairePersons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.

Timeline

Start date
2019-04-03
Primary completion
2020-10-03
Completion
2021-10-03
First posted
2018-09-14
Last updated
2026-04-13

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03671291. Inclusion in this directory is not an endorsement.